Quest Diagnostics Inc
NYSE:DGX
Quest Diagnostics Inc
NYSE:DGX
Price:
141.65 USD
0.62%
Updated:
May 16, 2024
P/E
Price to Earnings
Price to Earnings
18.6
Current
13.1
Median
23.9
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=18.6
Market Cap
/
15.7B
Net Income
842m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.7B USD | 18.6 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
90.3B EUR | 27.2 | |
| US |
|
Cigna Corp
NYSE:CI
|
97.2B USD | 26.9 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
72.2B USD | 9.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
18B USD | 41.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
16.1B EUR | -27.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12.3B EUR | 24.7 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
12.2B EUR | 24.5 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12.1B USD | 14.9 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -18.6 | |
| US |
|
Chemed Corp
NYSE:CHE
|
8.6B USD | 30.3 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
16
2-Years Forward
P/E
14.9
3-Years Forward
P/E
13.8
You don't have any saved screeners yet
